伊利诺伊州北芝加哥 - 艾伯维公司（纽约证券交易所代码：ABBV）和Gedeon Richter Plc.宣布达成协议，共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上，该合作关系已经产生了中枢神经系统疗法，包括cariprazine（VRAYLAR® / REAGILA®）和研究中的药物ABBV-932。

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. It is set to report its Q3 ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

On Thursday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $189.65 which represents a slight increase of $1.77 or 0.94% from the prior close of $187.88. The stock opened at $188.43 ...

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

American Institute for Advanced Investment Management LLP boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...